Abstract
Absorbable oxidized cellulose hemostatic materials are widely used in hemostasis of veins, capillaries or smaller arteries because of their wide sources, low cost, and high biocompatibility. However, in view of the different application sites, the hemostatic effect of absorbable oxidized cellulose in different surgeries may be different, and its hemostatic effect in patients with colorectal cancer still needs more research to confirm. Therefore, this article explores the in vitro degradation of the absorbable regenerated oxidized cellulose material and its hemostatic effect in colorectal cancer surgery. Explore the in vitro degradation products that can absorb oxidized cellulose. The 44 patients undergoing colon cancer surgery were selected and randomly divided into control group (22 cases, absorbable oxidized cellulose material to stop bleeding) and observation group (22 cases, ordinary Sterile gauze to stop bleeding). The intraoperative blood loss, 3 days postoperative drainage volume, total drainage volume, and operation time of the two groups were recorded. The recovery of intestinal function after operation in the two groups was observed. The in vitro complete degradation time of the absorbable oxidized cellulose material is about 12 days. The degradation products are glucose and cellobiose, which are safe and harmless to the human body. The intraoperative blood loss, drainage volume, total drainage volume, and operation time of the observation group were significantly lower than those of the control group (P <0.05), and the postoperative intestinal function recovery of the observation group was better than that of the control group (P <0.05). In addition, there was no significant difference in the incidence of adverse reactions between the observation group and the control group (P > 0.05). Absorbable oxidized cellulose material has a good hemostatic effect in colorectal cancer surgery, and does not increase the risk of adverse reactions in patients after surgery. It is worthy of popularization and application.
Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study
